4.5 Article

Characterization of a Complex Duchenne Muscular Dystrophy-Causing Dystrophin Gene Inversion and Restoration of the Reading Frame by Induced Exon Skipping

期刊

HUMAN MUTATION
卷 30, 期 1, 页码 22-28

出版社

WILEY
DOI: 10.1002/humu.20806

关键词

Duchenne muscular dystrophy; dystrophin; DMD; inversion; antisense oligonucleotides; AO; alternative splicing; cryptic exon

资金

  1. Muscular Dystrophy Association, Inc. (Western Australia)
  2. Medical and Health Research Infrastructure Fund (Western Australia)
  3. Action Duchenne (United Kingdom)
  4. National Institutes of Health [1R01 NS044146-02]
  5. Muscular Dystrophy Association, Inc. (USA) [3718, 4352]
  6. NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS044146] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Out of three mutations in the dystrophin gene that cause Duchenne muscular dystrophy (DMD), the most common, serious childhood muscle wasting disease, two are genomic deletions of one or more exons that disrupt the reading frame. Specific removal of an exon flanking a genomic deletion using antisense oligonucleotide intervention during pre-RNA processing can restore the reading frame and could potentially reduce disease severity. We describe a rare dystrophin gene rearrangement; inversion of similar to 28kb, flanked by a 10-bp duplication and an 11-kb deletion, which led to the omission of exons 49 and 50 from the mature mRNA and the variable inclusion of several pseudoexons. In vitro transfection of cultured patient cells with antisense oligonucleotides directed at exon 51 induced efficient removal of that exon, as well as one of the more commonly included pseudoexons, suggesting closely coordinated splicing of these exons. Surprisingly, several antisense oligonucleotides (AOs) directed at this pseudoexon had no detectable effect on the splicing pattern, while all AOs directed at the other predominant pseudoexon efficiently excised that target. Antisense oligomers targeting dystrophin exon 51 for removal are currently undergoing clinical trials. Despite the unique nature of the dystrophin gene rearrangement described here, a personalized multiexon skipping treatment is applicable and includes one compound entering clinical trials for DMD.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据